ArticleResearch square2025
Preclinical Evaluation of mTORC1 Inhibition via Rapamycin in Machine-Perfused Rodent Livers.
Article in Research square, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Normothermic machine perfusion (NMP) enables real-time liver viability assessment and therapeutic intervention during preservation. Rapamycin, an mTORC1 inhibitor known to induce autophagy and promote cellular resilience, represents a promising candidate for mitigating ischemic injury during NMP. We developed a rat model of warm ischemia followed by NMP to evaluate whether rapamycin improves liver graft quality. Livers were subjected to 90 minutes of warm ischemia and then perfused for three hours with or without 50nM rapamycin. While no significant differences were observed in perfusate oxygen consumption, lactate clearance, or transaminase release, histological analysis revealed that rapamycin-treated livers had improved cellular architecture and reduced necrosis compared to untreated controls. These findings suggest that rapamycin may confer structural protection independent of immediate metabolic changes. This model provides a platform to further study targeted therapies during NMP and supports the potential role of mTORC1 modulation in enhancing liver graft preservation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.